Impaired bone marrow microenvironment and stem cells in transfusion-dependent beta-thalassemia

Biomed Pharmacother. 2022 Feb:146:112548. doi: 10.1016/j.biopha.2021.112548. Epub 2021 Dec 16.

Abstract

Beta-thalassemia (BT) is a hereditary disease caused by abnormal hemoglobin synthesis with consequent ineffective erythropoiesis. Patients with thalassemia major are dependent on long-term blood transfusions with associated long-term complications such as iron overload (IO). This excess iron can result in tissue damage, impaired organ function, and increased morbidity. Growing evidence has demonstrated that IO contributes to impairment of the bone marrow (BM) microenvironment that largely impacts the function of BM mesenchymal stem cells, hematopoietic stem cells, and endothelial cells. In this article, we review recent progress in the understanding of iron metabolism and the perniciousness induced by IO. We highlight the importance of understanding the cross-talk between BM stem cells and the BM microenvironment, particularly the pathological effect of IO on BM stem cells and BT-associated complications. We also provide an update on recent novel therapies to cure transfusion-dependent beta-thalassemia and iron overload-induced complications for their future clinical application.

Keywords: Beta-thalassemia; Bone marrow stem cells; Endothelial cells; Homeostasis; Iron overload.

Publication types

  • Review

MeSH terms

  • Blood Transfusion
  • Bone Marrow / metabolism*
  • Bone Marrow Cells / metabolism*
  • Erythroid Cells / metabolism
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Iron / metabolism*
  • Iron Chelating Agents
  • Iron Overload / complications*
  • Iron Overload / physiopathology*
  • Iron Overload / therapy
  • Mesenchymal Stem Cells / metabolism
  • Stem Cell Niche / physiology
  • beta-Thalassemia / pathology
  • beta-Thalassemia / therapy

Substances

  • Iron Chelating Agents
  • Iron